Synaptic vesicle cycling is the fundamental process by which neurotransmitters are released from presynaptic terminals. This pathway encompasses vesicle mobilization, docking, fusion, release, and recycling. Dysregulation of these processes has emerged as a critical mechanism in neurodegenerative diseases, particularly Alzheimer's disease (AD) and Parkinson's disease (PD).
Synaptic vesicles exist in three main pools within the presynaptic terminal:
- Reserve Pool: Large vesicles tethered to cytoskeleton (actin, synapsin), released during intense stimulation
- Docked Pool: Vesicles physically attached to active zone membranes, ready for fusion
- Readily Releasable Pool (RRP): Vesicles immediately available for Ca²⁺-triggered release
- Vesicle Acidification: V-ATPase pumps protons into vesicles, creating electrochemical gradient
- Neurotransmitter Loading: Transporters (VGLUT, VMAT, VIAAT) fill vesicles with neurotransmitters
- Vesicle Docking: SNARE proteins (synaptobrevin, syntaxin, SNAP-25) mediate vesicle attachment
- Ca²⁺ Triggered Fusion: Synaptotagmin senses Ca²⁺ influx, catalyzes full fusion
- Endocytosis: Vesicle membrane retrieved via clathrin-mediated or bulk endocytosis
- Recycling: Vesicles are re-acidified and refilled for another cycle
In AD, synaptic dysfunction occurs early and correlates with cognitive decline:
- Presynaptic Proteins: Amyloid-beta oligomers bind to synaptic terminals, disrupting vesicle cycling
- SNARE Complex: Reduced syntaxin-1 and SNAP-25 levels impair vesicle fusion
- Synaptotagmin: Altered Ca²⁺ sensing contributes to release deficits
- Vesicle Trafficking: APP processing fragments disrupt vesicular transport
Synaptic vesicle dysfunction is central to PD pathogenesis:
- α-Synuclein: Binds to synaptic vesicles, altering neurotransmitter release
- VMAT2: Target of MPP⁺ toxicity; vesicular dopamine storage impaired
- Synaptic Fatigue: Enhanced depletion of vesicles during sustained firing
- Rab Proteins: Rab3 and Rab5 dysregulation affects vesicle cycling
- Synaptic Vesicle Depletion: Enhanced depletion during repetitive firing
- Calcium Buffering: Impaired calbindin affects Ca²⁺ handling in terminals
- Mitochondrial Dysfunction: Energy deficits impair vesicle recycling
¶ Key Proteins and Genes
| Protein |
Gene |
Function |
Neurodegeneration Link |
| Synaptophysin |
SYP |
Major vesicle protein |
Reduced in AD |
| Synaptotagmin-1 |
SYT1 |
Ca²⁺ sensor for release |
Dysregulated in PD |
| Synaptobrevin-2 |
VAMP2 |
v-SNARE for fusion |
Cleaved in tetanus |
| SNAP-25 |
SNAP25 |
t-SNARE |
Reduced in AD |
| Syntaxin-1 |
STX1 |
t-SNARE |
Target of toxins |
| VGLUT1 |
SLC17A6 |
Glutamate transport |
Reduced in AD |
| VMAT2 |
SLC18A2 |
Dopamine transport |
PD therapeutic target |
| Rab3A |
RAB3A |
Vesicle trafficking |
Impaired in PD |
- Glutamate: Impaired release affects excitatory signaling
- GABA: Reduced inhibition contributes to network dysfunction
- Dopamine: Altered vesicle dynamics in PD striatum
- Acetylcholine: Basal forebrain cholinergic deficits in AD
- Long-term Potentiation (LTP): Vesicle cycling deficits impair synaptic strengthening
- Long-term Depression (LTD): Altered release affects synaptic weakening
- Homeostatic Plasticity: Failure to compensate for degenerating inputs
- Synaptic Mitochondria: Energy deficits affect vesicle ATP supply
- Cytoskeletal Disruption: Impaired vesicle transport along axons
- Terminal Degeneration: Synaptic loss precedes cell body death
- Vesicle Modulators: Compounds enhancing vesicle cycling
- Synaptic Stabilizers: Protecting SNARE complex integrity
- Calcium Modulators: Normalizing Ca²⁺ signaling in terminals
- Viral Vector Delivery: Expressing wild-type synaptic proteins
- RNAi/ASO: Targeting pathological protein aggregates
- CRISPR: Editing susceptibility genes
- α-Synuclein Aggregation Inhibitors: Protecting synaptic function
- Amyloid-Targeting: Reducing toxic oligomeric species
- Neurotrophic Factors: Supporting synaptic maintenance
- [Selkoe, Synaptic dysfunction in AD (2002)](https://doi.org/10.1038/415 Pt 2):377-383
- Bellucci et al., α-Synuclein and synaptic dysfunction (2020)
- Sheng & Cai, Synaptic mitochondria in neurodegeneration (2012)
- Burré et al., α-Synuclein and SNARE complex (2015)
- Mukherjee et al., Synaptic vesicle cycling in AD (2020)
- Südhof, Synaptic vesicle exocytosis (2013)
- Gillingwater & Wishart, Synaptic vulnerability in ALS (2013)
- Kelley et al., Synaptic vesicle proteins in AD (2018)